Definium Therapeutics, Inc. (DFTX) — Cash Flow-to-Debt Ratio
Definium Therapeutics, Inc. (DFTX) has a Cash Flow-to-Debt Ratio of -0.39x as of December 2025, meaning its operating cash flow of $-41.89 Million could theoretically repay 0% of its total liabilities ($107.77 Million) in one year. Explore Definium Therapeutics, Inc. (DFTX) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Definium Therapeutics, Inc. Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Definium Therapeutics, Inc. across 11 annual periods. Also explore Definium Therapeutics, Inc. balance sheet assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Definium Therapeutics, Inc. (2015–2025)
Year-by-year debt coverage analysis for Definium Therapeutics, Inc.. For market capitalisation and broader financial context, see DFTX market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.22x | $-131.56 Million | $107.77 Million | ▲ +6.4% |
| 2024 | -1.30x | $-79.13 Million | $60.70 Million | ▲ +6.0% |
| 2023 | -1.39x | $-64.36 Million | $46.41 Million | ▲ +47.2% |
| 2022 | -2.63x | $-50.14 Million | $19.08 Million | ▲ +29.2% |
| 2021 | -3.71x | $-45.82 Million | $12.34 Million | ▲ +11.1% |
| 2020 | -4.18x | $-23.60 Million | $5.65 Million | ▼ -299.2% |
| 2019 | -1.05x | $-208.12K | $198.96K | ▲ +98.8% |
| 2018 | -87.79x | $-722.45K | $8.23K | ▼ -960.4% |
| 2017 | -8.28x | $-665.98K | $80.44K | ▼ -2245.8% |
| 2016 | -0.35x | $-26.64K | $75.47K | ▲ +94.3% |
| 2015 | -6.22x | $-46.56K | $7.49K | — |